TNYA

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• FDA granted Tenaya Therapeutics RMAT Designation for TN-401 to treat PKP2-associated arrhythmogenic right ventricular cardiomyopathySep 15, 2026
• Tenaya Therapeutics reported interim MyPEAK-1 data showing cardiac improvements with TN-201 gene therapyJun 3, 2026
• Tenaya Therapeutics reports positive interim data from RIDGE™-1 Phase 1b/2 trial of TN-401 gene therapy in PKP2-associated ARVCDec 12, 2025
• Promising potential of Tenaya Therapeutics' TN-201 gene therapy in addressing pediatric hypertrophic cardiomyopathy: analyst recommends buySep 2, 2025
• Tenaya receives positive safety reviews from independent DSMBs for advancing TN-201 and TN-401 gene therapy clinical trialsJul 30, 2025